News
Shares of Novo Nordisk skidded on Tuesday as the Danish drugmaker reduced its expectations on wildly popular drugs Ozempic ...
Shares in Wegovy maker Novo Nordisk continued to slide on Wednesday as analysts warned of persistent competition from copycat ...
Novo Nordisk faces slowing demand, rising competition, and CEO transition. Learn about challenges impacting its growth and ...
Mange investorer har mistet tilliden til Novo Nordisk, fordi ledelsen har måttet sænke forventningerne til vækst og overskud.
Ude af det fine selskab Novos nedtur står i skarp kontrast til de væksttal, som sværvægteren med hovedsæde i Bagsværd de seneste år har kunnet fremvise. Novo Nordisk var i marts 2024 oppe som nummer ...
Novo Nordisk -aktien blev tirsdag sendt ud i et historisk kursfald på over 23 procent. Det er det største éndagsfald i ...
Novo Nordisk said it expects weaker sales growth of its popular weight-loss drug Wegovy due to competition from copycat drugs ...
Novo Nordisk har både selv og via sin ejer, Novo Nordisk Fonden, satset et trecifret milliardbeløb på at have kapaciteten til vækst. De enorme investeringer kan vise sig at have været forkerte, hvis ...
Danish leader will face a challenging landscape among competitors ...
Den danske medicinalkoncern Novo Nordisk er blevet trukket ind i skandale, hvor et tjekkisk medicinalfirma kræver 2 milliarder kroner af staten.
Compounding pharmacies are crimping sales of Novo Nordisk's obesity drug Wegovy by making what are essentially copies of the name-brand medicine. The company says it trying to stop them.
A version of this article appears in print on May 17, 2025, Section B, Page 5 of the New York edition with the headline: Novo Nordisk, Its Stock Falling and Competition Rising, Will Replace Its C ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results